Skip to main content

Clinical Trial Development

In order to increase clinical research and clinical trial development, Hollings leadership created the Hollings Advisory for Rapid Translation (HART). The HART Program brings an expert team in trial concept development directly to faculty members seeking to translate their findings to the clinic. HART provides investigators mentorship in navigating the decision points from concept development to implementation and ensures the investigator is connected to appropriate resources to help reduce barriers to protocol activation.

Trial Development Steps

Expand the buttons below for details on clinical trial development and ways that HART can assist with the process. To request assistance with a trial concept, reach out at the link below.

HART will help review the trial concept and connect the PI to members of the TCTs, Clinical Research Groups, Sponsor Investigator Support Unit (SISU), and Biostatistics Shared Resource (BSR), all of which provide valuable insight into the development of a feasible and meritorious clinical trial.

The current version of the NIH-FDA protocol template is used to develop the study protocol. The SISU and Biostatistics Shared Resource work closely with the PI to draft sections of the protocol and support revisions of the protocol and related regulatory documents as the study moves through the regulatory review process.

Once completed, the SISU will submit the protocol and any other documents (i.e., consent forms, patient facing materials) to the FDA, PRC, IRB and/or any other applicable committees/boards for approval. The SISU will provide you with a timeline for when your study will be reviewed and activated for enrollment.

It is important to work with the SISU and our CTO pre-award finance team to develop a budget for the clinical trial. Our team can help investigators obtain a required coverage analysis to determine what are research specific procedures versus standard of care charges that can be billed to the study patient. Additionally, the team can build a draft budget that matches the coverage analysis and anticipated enrollment plan.

While it is recommended that the investigator seek external or intramural funding to support the clinical trial, Hollings Cancer Center has established the Clinical Trials Investment Program (CTIP) to support high priority investigator-initiated treatment trials that have financial feasibility concerns. Eligibility for funding is reviewed by HART leaders. To request CTIP funding, submit an application via the InfoReady portal.

Once your study has been approved, the SISU will ensure that the appropriate clinical study team is trained and supported for patient enrollment and interventions on your study. All patients who are enrolled will be entered into the REDCap electronic data capture system developed by the BSR. The SISU and BSR will closely monitor the input of patient information and ensure that the information is complete and entered in a timely manner.

Request Assistance

If you have questions or need further assistance with a clinical trial concept, please contact us and someone from the HART team will reach out to you. An MUSC NetID and password are required.

Contact HART

HART Leadership

John M. Wrangle, M.D., MPH

Associate Professor
HART Scientific Director, MUSC Hollings Cancer Center

Ozgur Sahin, Ph.D.

Professor, Biochemistry & Molecular Biology